Press releases // 05 March 2019
IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test

IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.